TL;DR: Trulieve Cannabis (OTC: TCNNF) heads into the week of June 29 with a strengthened fundamental thesis as April’s federal medical rescheduling begins reducing its 280E tax burden. With the DOJ’s adult-use Schedule III hearings entering their final phase, Trulieve’s Florida-centric retail network — the largest single-state dispensary footprint in the U.S. — stands as one of the most leveraged plays on continued regulatory progress. Q2 2026 results, expected in August, will be the first to fully reflect the April medical Schedule III order.
Market Analysis
Trulieve’s competitive moat in cannabis retail has always been its concentration in Florida, where it operates more than 130 dispensaries — a retail density that would be uneconomical in most industries but has proven strategically sound in a market where state licensing remains restrictive. The company’s Q1 2026 results reflected the early stages of 280E normalization following the April medical rescheduling of cannabis to Schedule III status. Federal tax savings flowed directly to EBITDA, with Trulieve reporting improved after-tax cash margins even as total revenue held relatively flat.
For Q2 2026 — results expected in August — investors will see the first full quarter of medical Schedule III treatment. Analysts following the sector estimate that Trulieve’s effective federal tax rate dropped from approximately 70–80% of taxable income (under 280E) to a more conventional 21% corporate rate on federally taxable income for Schedule III-compliant revenue. That swing is not marginal: for a company generating $300+ million in quarterly revenue, the difference is measured in tens of millions of dollars of retained cash flow.
Year-to-date, TCNNF has moved broadly in line with the MSOS ETF, though it has lagged the ETF’s strongest weeks given its limited institutional ownership and the stock’s OTC status. The Delaware redomicile trend — which Curaleaf shareholders approved last week — is a path Trulieve management has also discussed, and uplisting to a major exchange would be a material re-rating catalyst if executed.
Regulatory and Market Context
The rescheduling trajectory remains the dominant macro driver for all U.S. multi-state operators, but Trulieve’s position is amplified by Florida’s political dynamics. Florida voters narrowly rejected adult-use legalization in November 2024 (Amendment 3 received approximately 56.7% in favor, falling short of the 60% supermajority required). That rejection was a short-term headwind, but it also preserved Trulieve’s protected medical market position longer than critics expected — and the company has used that window to strengthen its balance sheet and expand production capacity.
The DOJ’s adult-use rescheduling hearings, which entered Day 2 on June 26, could eventually create a federal framework that influences state-level adult-use timelines in ways that ballot measures alone cannot. For Florida — where the 60% supermajority requirement creates a near-structural barrier — federal rescheduling represents the most plausible path to commercial adult-use without another ballot cycle. Management has indicated it is preparing for adult-use operations with infrastructure investments already underway.
Meanwhile, the company’s competitor set in Florida has thinned. Several smaller vertically integrated operators have struggled to sustain capital under 280E constraints and Florida’s high compliance costs. Trulieve’s balance sheet, while carrying debt from its 2021 Harvest Health acquisition, has improved relative to peers as sector refinancing activity picks up.
Tracking TCNNF alongside the broader cannabis equity universe is straightforward through the cannabis stock tracker, which monitors Trulieve and the full MSO peer group in real time.
Conclusion
The inflection point for Trulieve investors is not Florida adult-use legalization — that remains speculative. The near-term catalyst is the Q2 2026 earnings print and whether 280E savings translate into the kind of free cash flow that institutional cannabis funds require before adding material positions. Short interest in TCNNF remains elevated relative to pre-rescheduling levels, suggesting the market is still pricing in meaningful regulatory risk. If the DOJ hearings conclude without disruption to the adult-use proceeding, that short overhang could compress meaningfully heading into Q3 2026 — making the next 60 days a potentially pivotal window for the stock.